- Home
- COSM
COSM
Cosmos Health Inc.
as 05-15-2025 4:00pm EST
Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.
| Founded: | 2009 | Country: | Greece |
| Employees: | N/A | City: | THESSALONIKI |
| Market Cap: | 8.2M | IPO Year: | 2013 |
| Target Price: | N/A | AVG Volume (30 days): | 814.2K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.17 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.28 - $1.58 | Next Earning Date: | 05-15-2025 |
| Revenue: | $54,426,402 | Revenue Growth: | 1.97% |
| Revenue Growth (this year): | 28.14% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Cosmos Health Inc. (COSM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Siokas Grigorios | COSM | Chief Executive Officer | Apr 24 '25 | Buy | $0.40 | 177,234 | $70,999.94 | 5,327,448 | |
| Siokas Grigorios | COSM | Chief Executive Officer | Apr 23 '25 | Buy | $0.40 | 205,000 | $82,000.00 | 5,327,448 | |
| Siokas Grigorios | COSM | Chief Executive Officer | Apr 22 '25 | Buy | $0.36 | 175,000 | $63,000.00 | 5,327,448 | |
| Siokas Grigorios | COSM | Chief Executive Officer | Mar 4 '25 | Buy | $0.53 | 85,714 | $44,999.85 | 5,327,448 | |
| Siokas Grigorios | COSM | Chief Executive Officer | Mar 3 '25 | Buy | $0.49 | 132,572 | $65,000.05 | 5,327,448 | |
| Siokas Grigorios | COSM | Chief Executive Officer | Feb 24 '25 | Buy | $0.56 | 354,296 | $200,000.09 | 5,327,448 |
Latest Cosmos Health Inc. News
COSM Breaking Stock News: Dive into COSM Ticker-Specific Updates for Smart Investing
GlobeNewswire
13 hours ago
Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven
GlobeNewswire
8 days ago
Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units
GlobeNewswire
9 days ago
Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq
GlobeNewswire
15 days ago
Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000
Argus Research
17 days ago
Daily – Vickers Top Buyers & Sellers for 04/29/2025
Argus Research
22 days ago
Daily – Vickers Top Buyers & Sellers for 04/24/2025
GlobeNewswire
a month ago
Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million
GlobeNewswire
a month ago
Cosmos Health Further Expands Facility Upgrades Program at Cana Laboratories and Signs 5-Year Contract Manufacturing Agreement with Pharmex for 1.5 Million Bottles of the Antiseptic Drug AMBITASOL 1L
Compare COSM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "COSM Cosmos Health Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.